1,969 reports of this reaction
2.2% of all DAPAGLIFLOZIN reports
#6 most reported adverse reaction
DYSPNOEA is the #6 most commonly reported adverse reaction for DAPAGLIFLOZIN, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,969 FDA adverse event reports linking DAPAGLIFLOZIN to DYSPNOEA. This represents approximately 2.2% of all 89,435 adverse event reports for this drug.
Patients taking DAPAGLIFLOZIN who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for DAPAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for DAPAGLIFLOZIN:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,969 FDA reports for DAPAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.2% of all adverse event reports for DAPAGLIFLOZIN, making it a notable side effect.
If you experience dyspnoea while taking DAPAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.